ESPR Stock Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
Esperion Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.51|
|52 Week High||US$26.77|
|52 Week Low||US$3.28|
|1 Month Change||5.56%|
|3 Month Change||31.50%|
|1 Year Change||-72.72%|
|3 Year Change||-88.67%|
|5 Year Change||-83.02%|
|Change since IPO||-62.00%|
Recent News & Updates
Esperion Therapeutics: 2021 Labors Paying Off In 2022
Esperion Therapeutics reported their Q1 earnings that revealed a beat on EPS and revenue. The company reported $13.4M in U.S. product revenue for Q1, which was up around 109% year-over-year. Esperion had a 32% year-over-year cost savings of the company operating expenses compared to the first quarter of 2021. The company believes they are "financed through the readout of the CLEAR Outcomes trial and for the foreseeable future beyond that". I believe investors should be applauding Esperion's recent success and ought to be enthusiastic about the company’s long-term potential.
|ESPR||US Pharmaceuticals||US Market|
Return vs Industry: ESPR underperformed the US Pharmaceuticals industry which returned 13.6% over the past year.
Return vs Market: ESPR underperformed the US Market which returned -15.1% over the past year.
|ESPR Average Weekly Movement||12.0%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ESPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ESPR's weekly volatility (12%) has been stable over the past year.
About the Company
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
Esperion Therapeutics Fundamentals Summary
|ESPR fundamental statistics|
Is ESPR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ESPR income statement (TTM)|
|Cost of Revenue||US$121.90m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.73|
|Net Profit Margin||-263.03%|
How did ESPR perform over the long term?See historical performance and comparison
Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ESPR ($5.51) is trading below our estimate of fair value ($69.32)
Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ESPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Pharmaceuticals industry average.
PE vs Market: ESPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ESPR has negative assets, so we can't compare its Price-To-Book Ratio to the US Pharmaceuticals industry average.
How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ESPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ESPR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ESPR's is expected to become profitable in the next 3 years.
Revenue vs Market: ESPR's revenue (45.2% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: ESPR's revenue (45.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time
How has Esperion Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ESPR is currently unprofitable.
Growing Profit Margin: ESPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of 13.6% per year.
Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Return on Equity
High ROE: ESPR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Esperion Therapeutics's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ESPR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ESPR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ESPR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESPR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ESPR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ESPR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sheldon Koenig (55 yo)
Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...
CEO Compensation Analysis
Compensation vs Market: Sheldon's total compensation ($USD7.78M) is above average for companies of similar size in the US market ($USD2.63M).
Compensation vs Earnings: Sheldon's compensation has increased whilst the company is unprofitable.
Experienced Management: ESPR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: ESPR's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ESPR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 123.5%.
Esperion Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Esperion Therapeutics, Inc.
- Ticker: ESPR
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$347.166m
- Shares outstanding: 63.01m
- Website: https://www.esperion.com
Number of Employees
- Esperion Therapeutics, Inc.
- 3891 Ranchero Drive
- Suite 150
- Ann Arbor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.